EE03039B1 - Meetod hüdrateeritud tsefalosporiini kuiva pulbrilise segu valmistamiseks, sellel meetodil valmistatud segu ja farmatseutilised kompositsioonid - Google Patents

Meetod hüdrateeritud tsefalosporiini kuiva pulbrilise segu valmistamiseks, sellel meetodil valmistatud segu ja farmatseutilised kompositsioonid

Info

Publication number
EE03039B1
EE03039B1 EE9400249A EE9400249A EE03039B1 EE 03039 B1 EE03039 B1 EE 03039B1 EE 9400249 A EE9400249 A EE 9400249A EE 9400249 A EE9400249 A EE 9400249A EE 03039 B1 EE03039 B1 EE 03039B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
dry powder
hydrated
pct
cephalosporins
Prior art date
Application number
EE9400249A
Other languages
English (en)
Estonian (et)
Inventor
A. Johnson Donald
Wearley Lorraine
Galeos Rebecca
A. Sequeira Joel
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of EE03039B1 publication Critical patent/EE03039B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
EE9400249A 1992-04-30 1994-11-21 Meetod hüdrateeritud tsefalosporiini kuiva pulbrilise segu valmistamiseks, sellel meetodil valmistatud segu ja farmatseutilised kompositsioonid EE03039B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87688192A 1992-04-30 1992-04-30

Publications (1)

Publication Number Publication Date
EE03039B1 true EE03039B1 (et) 1997-10-15

Family

ID=25368763

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400249A EE03039B1 (et) 1992-04-30 1994-11-21 Meetod hüdrateeritud tsefalosporiini kuiva pulbrilise segu valmistamiseks, sellel meetodil valmistatud segu ja farmatseutilised kompositsioonid

Country Status (23)

Country Link
US (1) US5599557A (de)
EP (1) EP0642344B1 (de)
JP (1) JP3378004B2 (de)
KR (1) KR100257803B1 (de)
AT (1) ATE150310T1 (de)
AU (1) AU674516B2 (de)
CA (1) CA2134467A1 (de)
CZ (1) CZ283428B6 (de)
DE (1) DE69309052T2 (de)
DK (1) DK0642344T3 (de)
EE (1) EE03039B1 (de)
ES (1) ES2099438T3 (de)
FI (1) FI945081A7 (de)
GR (1) GR3023516T3 (de)
HK (1) HK1002407A1 (de)
HU (1) HU215958B (de)
NO (1) NO307594B1 (de)
NZ (1) NZ252433A (de)
PL (1) PL171630B1 (de)
RU (1) RU2123863C1 (de)
SK (1) SK279329B6 (de)
UA (1) UA27899C2 (de)
WO (1) WO1993021923A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
EP2172223B1 (de) * 2007-06-22 2020-12-16 Kaneka Corporation Eine physiologisch wirksame substanz enthaltende zusammensetzung
EP2186789B1 (de) * 2007-08-22 2013-12-25 Kaneka Corporation Verfahren zur herstellung von reduziertem coenzym q10 und verfahren zu seiner stabilisierung
WO2011139253A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
RU2550932C1 (ru) * 2014-03-18 2015-05-20 Александр Александрович Кролевец Способ получения нанокапсул цефалоспориновых антибиотиков в ксантановой камеди
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4803082A (en) * 1987-10-28 1989-02-07 Warner-Lambert Company Flavor and sweetness enhancement delivery systems and method of preparation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation

Also Published As

Publication number Publication date
DE69309052D1 (de) 1997-04-24
CA2134467A1 (en) 1993-11-11
RU2123863C1 (ru) 1998-12-27
SK279329B6 (sk) 1998-10-07
HU9403108D0 (en) 1995-02-28
EP0642344B1 (de) 1997-03-19
FI945081L (fi) 1994-10-28
KR100257803B1 (en) 2000-08-01
JP3378004B2 (ja) 2003-02-17
ATE150310T1 (de) 1997-04-15
CZ283428B6 (cs) 1998-04-15
US5599557A (en) 1997-02-04
PL171630B1 (pl) 1997-05-30
DK0642344T3 (da) 1997-07-07
HK1002407A1 (en) 1998-08-21
RU94046038A (ru) 1996-11-10
FI945081A0 (fi) 1994-10-28
AU674516B2 (en) 1997-01-02
HUT71226A (en) 1995-11-28
SK131194A3 (en) 1995-07-11
KR950701224A (ko) 1995-03-23
JPH07506366A (ja) 1995-07-13
NO944113D0 (no) 1994-10-28
NO307594B1 (no) 2000-05-02
NO944113L (no) 1994-10-28
DE69309052T2 (de) 1997-06-19
EP0642344A1 (de) 1995-03-15
UA27899C2 (uk) 2000-10-16
HU215958B (hu) 1999-03-29
WO1993021923A1 (en) 1993-11-11
ES2099438T3 (es) 1997-05-16
GR3023516T3 (en) 1997-08-29
CZ263694A3 (en) 1995-04-12
NZ252433A (en) 1996-07-26
AU4115293A (en) 1993-11-29
FI945081A7 (fi) 1994-10-28

Similar Documents

Publication Publication Date Title
KR100257803B1 (en) Stable hydrated cephalosporin dry powder for oral suspension formulation
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
ES8608864A1 (es) Un procedimiento para producir un preparado a modo de hojas
EP0221041A3 (de) Benzimidazolderivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
HUT47130A (en) Process for producing 9alpha-hydroxysteroids, as well as 9(11)-dehydro derivatives and pharmaceutical compositions comprising these active ingredients
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
IL84944A (en) Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
PL311122A1 (en) Water-solublederivatives of camptotectin, method of obtaining them and their application as anticarcinogenic agents
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
ZA848140B (en) New benzenesulfonyl-lactams,process for their preparation and their use as active substances of pharmaceutical compositions
EP0104768A3 (de) NG Acyl-argininderivate enthaltende orale Präparate
ES8404852A1 (es) Procedimiento para preparar derivados de acidos isoquinolein-4-carboxilicos
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
TW261605B (de)
ATE68178T1 (de) 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
IL105391A0 (en) 1,2,4-benzothiadiazine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
HU9302813D0 (en) Pharmaceutical compositions containing new benzimidazole derivatives and process for preparing the active ingredients
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
AU565187B2 (en) 2-n-cycloalkylmethyl-3-oxo-5,6-diaryl-as-triazines
IT8024152A0 (it) Derivati dell'1,1,2-trifenilpropano e dell'1,1,2-trifenilpropene, procedimento per la loro preparazione e composizioni farmaceutiche contenenti i composti
FI915930A7 (fi) Uudet 15-nitro-2B, 3B-dihydro- ja nitro-2B, 3B, 6,7-tetrahydrotaversoniinijohdannaiset, farmaseuttiset koostumukset, jotka sisältävät niitä ja niiden valmistusmenetelmä
ES2076614T3 (es) Masa de goma de mascar, procedimiento para su fabricacion y uso.
IL64839A (en) N-arylmethyl-4-(methylanilino)-5-sulfamoyl-anthranilic acids,a process for their preparation and pharmaceutical compositions containing them
IL67400A0 (en) 3,7alpha-diazacyclohepta(j,k)fluorene derivatives,their preparation and pharmaceutical compositions containing them